Pfizer Breaks Ground on New Andover, MA Facility

Pfizer kicked off a $200 million development project Thursday at its Andover, MA campus, where the company plans on building a new 170,000 sq ft biologics clinical manufacturing facility.

The five-story building, anticipated to be operational by January 2019, will house 75 new employees who will produce vaccines and biologics, a Pfizer press release said.

“The expansion of Pfizer’s presence in Andover will provide state-of-the-art manufacturing to help bring new medicines and vaccines to the patients we serve,” John Ludwig, senior vice president of Pfizer research and development’s BioTheraputics pharmaceutical sciences unit said in the release. “Andover is a crucial part of our global footprint for both clinical and commercial manufacturing, and we believe it provides an attractive location for growth in the coming years.”

Designed with five independent manufacturing suites, the company said the facility will use “flexible design” to further its “Next Generation Manufacturing” strategies; implement single-use bioreactors and disposable process technologies; and “provide clinical manufacturing options with the lowest cost and greatest flexibility.”

Pfizer’s Andover campus currently has seven buildings and employs 1200 people. 200 temporary construction jobs will be created through the development project.